Belgia - hollanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

synthon b.v. - tamsulosinehydrochloride 0,4 mg - capsule met gereguleerde afgifte, hard - 0,4 mg - tamsulosinehydrochloride 0.4 mg - tamsulosin

Euroopan unioni - hollanti - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Euroopan unioni - hollanti - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 en 5. 1 voor de beschikbare gegevens over verschillende combinaties).

Euroopan unioni - hollanti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

accord healthcare b.v. winthontlaan 200 3526 kv utrecht - naltrexonhydrochloride 50 mg/stuk samenstelling overeenkomend met ; naltrexon 45,2 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; crospovidon (e 1202) ; hypromellose (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; hypromellose (e 464) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 400 ; magnesiumstearaat (e 470b) ; polysorbaat 80 (e 433) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - naltrexone

Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - metforminehydrochloride - filmomhulde tablet - hypromellose (e 464) ; magnesiumstearaat (e 470b) ; polyethyleenglycol (e 1521) ; povidon (e 1201), - metformin

Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - metforminehydrochloride - filmomhulde tablet - hypromellose (e 464) ; magnesiumstearaat (e 470b) ; polyethyleenglycol (e 1521) ; povidon (e 1201), - metformin

Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - metforminehydrochloride - filmomhulde tablet - hypromellose (e 464) ; magnesiumstearaat (e 470b) ; polyethyleenglycol (e 1521) ; povidon (e 1201), - metformin

Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

tiofarma b.v. benjamin franklinstraat 5-10 3261 lw oud-beijerland - pyridoxinehydrochloride 50 mg/ml samenstelling overeenkomend met ; pyridoxine 41,1 mg/ml - oplossing voor injectie - dinatriumedetaat 2-water ; natriumhydroxide (e 524) ; stikstof (head space) (e 941) ; water voor injectie, - pyridoxine (vit b6)

Alankomaat - hollanti - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

genthon b.v. microweg 22 6545 cm nijmegen - tamsulosinehydrochloride 0,4 mg/stuk samenstelling overeenkomend met ; tamsulosine 0,37 mg/stuk - capsule met gereguleerde afgifte, hard - cellulose, microkristallijn (e 460(i)) ; copolymeer van ethylacrylaat-methacrylzuur (1:1) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; natriumlaurilsulfaat ; polysorbaat 80 (e 433) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505), cellulose, microkristallijn (e 460) ; copolymeer van ethylacrylaat-methacrylzuur (1:1) ; gelatine (e 441) ; ijzeroxide geel (e 172) ; ijzeroxide rood (e 172) ; ijzeroxide zwart (e 172) ; indigokarmijn (e 132) ; natriumlaurilsulfaat (e 487) ; polysorbaat 80 (e 433) ; talk (e 553 b) ; titaandioxide (e 171) ; triethylcitraat (e 1505), - tamsulosin